Anemia in HIV infection: clinical impact and evidence-based management strategies.
Anemia in HIV infection: clinical impact and evidence-based management strategies.
复制标题
DOI：
10.1086/383031
复制
发表时间：
2004-05-15
期刊：
影响因子：
--
通讯作者：
Saag, Michael
中科院分区：
文献类型：
--
作者：
Volberding, Paul A;Levine, Alexandra M;Saag, Michael
人类免疫缺陷病毒（HIV）感染患者的贫血可能具有严重的影响，从功能和生活质量下降到与疾病进展和生存率下降相关。2002年，艾滋病毒感染者贫血问题工作组的16名成员再次开会，评估新的数据，并将这些数据转化为循证治疗准则。该小组就高活性抗逆转录病毒治疗时代贫血的患病率达成共识;与贫血发展独立相关的危险因素;贫血对生活质量，身体功能和生存的影响;丙型肝炎病毒合并感染治疗对艾滋病毒感染患者贫血的影响; HIV感染患者贫血治疗的循证指南，包括依泊苷α的治疗作用;以及未来研究的方向。
Anemia in human immunodeficiency virus (HIV)-infected patients can have serious implications, which vary from functional and quality-of-life decrements to an association with disease progression and decreased survival. In 2002, 16 members of the Anemia in HIV Working Group, an expert panel of physicians involved in the care of HIV-infected patients that met first in 1998, reconvened to assess new data and to translate these data into evidence-based treatment guidelines. The group reached consensus on the prevalence of anemia in the highly active antiretroviral therapy era; the risk factors that are independently associated with the development of anemia; the impact of anemia on quality of life, physical functioning, and survival; the impact of the treatment of hepatitis C virus coinfection on anemia in HIV-infected patients; evidence-based guidelines for treatment of anemia in HIV-infected patients, including the therapeutic role of epoetin alfa; and directions for future research.